Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Altacor, an ophthalmic pharmaceutical company, has concluded an exclusive worldwide licensing agreement with Ophthalmopharma for the Age Related Macular Degeneration (AMD) nutritional product EYEBAR.
Subscribe to our email newsletter
The agreement is a second transaction between Altacor and Ophthalmopharma in which Altacor assumes responsibilities for their entire portfolio of ophthalmic products covering development, IP and commercialisation of the products.
EYEBAR is an antioxidant rich chocolate vitamin and mineral mixture which overcomes the palatability problems associated with traditional AREDS (Age Related Eye Disease Study ) nutritional products for AMD.
AREDS is sponsored by the US National Eye Institute which comprises of two studies AREDS1 and AREDS2.
AREDS1 (a high dose combination of vitamin C, vitamin E, beta-carotene, zinc oxide and cupric oxide) is a six-year clinical investigation in 4757 patients which has been concluded.
AREDS2 is an ongoing, follow-up study utilising a similar formula which replaces beta carotene with lutein and zeaxanthin.